Pyxis Oncology, Inc.
PYXS
$1.70
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 11.04M | -- | 2.82M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 11.04M | -- | 2.82M | -- |
| Cost of Revenue | -- | 2.39M | -- | -- | -- |
| Gross Profit | -- | 8.65M | -- | 2.82M | -- |
| SG&A Expenses | 3.75M | 4.54M | 4.97M | 4.75M | 5.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.73M | 28.64M | 22.78M | 21.89M | 22.40M |
| Operating Income | -23.73M | -17.60M | -22.78M | -19.07M | -22.40M |
| Income Before Tax | -23.27M | -17.00M | -22.00M | -18.07M | -21.16M |
| Income Tax Expenses | -- | 1.10M | -- | 283.00K | -- |
| Earnings from Continuing Operations | -23.27M | -18.11M | -22.00M | -18.35M | -21.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.27M | -18.11M | -22.00M | -18.35M | -21.16M |
| EBIT | -23.73M | -17.60M | -22.78M | -19.07M | -22.40M |
| EBITDA | -22.60M | -14.71M | -22.25M | -18.53M | -21.85M |
| EPS Basic | -0.37 | -0.29 | -0.35 | -0.30 | -0.35 |
| Normalized Basic EPS | -0.23 | -0.17 | -0.22 | -0.18 | -0.22 |
| EPS Diluted | -0.37 | -0.29 | -0.35 | -0.30 | -0.35 |
| Normalized Diluted EPS | -0.23 | -0.17 | -0.22 | -0.18 | -0.22 |
| Average Basic Shares Outstanding | 63.47M | 63.03M | 62.56M | 61.92M | 61.05M |
| Average Diluted Shares Outstanding | 63.47M | 63.03M | 62.56M | 61.92M | 61.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |